التفاصيل البيبلوغرافية
| العنوان: |
Infectious Disease Screening prior to Systemic Immunomodulatory Therapy in Hidradenitis Suppurativa: Consensus Guidelines from the Asia-Pacific Hidradenitis Suppurativa Foundation. |
| المؤلفون: |
Kozera, Emily K., Porter, Martina, Paek, So Yeon, Mintoff, Dillon, McMeniman, Erin, Oon, Hazel H., Chandran, Nisha Suyien, Glasenhardt, Katalin, Ring, Hans Christian, Frew, John W. |
| المصدر: |
Dermatology (10188665); 2024, Vol. 240 Issue 3, p494-506, 13p |
| مصطلحات موضوعية: |
MEDICAL screening, HIDRADENITIS suppurativa, COMMUNICABLE diseases, ENDEMIC diseases, DELPHI method, HEPATITIS C, CHRONIC hepatitis B |
| مستخلص: |
Background: Current infectious disease screening recommendations for hidradenitis suppurativa (HS) are adopted from recommendations in chronic plaque psoriasis. No HS-specific guidelines for infectious disease screening prior to immunomodulatory therapy have been developed. Objectives: The aim of the study was to establish an expert Delphi consensus of recommendations regarding infectious disease screening prior to systemic immunomodulatory therapy in HS. Methods: Participants were identified via recent publications in the field and were sent a questionnaire regarding infectious diseases encountered in the setting of HS, and opinions regarding infectious disease screening prior to various systemic immunomodulatory therapies. All questions were informed by a systematic literature review regarding infections exacerbated or precipitated by immunomodulatory therapy. Questionnaire responses were followed by round-table discussion with a core group of 8 experts followed by a final round of questionnaires resulting in achievement of consensus. Results: 44 expert HS physicians from 12 countries on 5 continents participated in the development of the expert consensus recommendations. Consensus recommendations include screening for hepatitis B, hepatitis C and tuberculosis in all individuals with HS prior to therapy. All immunomodulatory therapies (biologic and systemic immunosuppressant therapy) should be preceded by infectious disease screening including patient and location-specific considerations for endemic local diseases and high-risk activities and occupations. Clinical assessment has a significant role in determining the need for laboratory screening in the setting of many uncommon or tropical diseases such as leprosy, leishmaniasis and strongyloidiasis. Conclusions: The presented consensus recommendations are the first specifically developed for pre-treatment infectious disease screening in HS. [ABSTRACT FROM AUTHOR] |
|
Copyright of Dermatology (10188665) is the property of Karger AG and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
